DRUG POLICY ALLIANCE NATIONAL CONFERENCE UNDERWAY IN NEW JERSEY

State Ripped for Leading Nation in Drug-Incarceration Rate

Hundreds of drug reformers, activists, academics, treatment
professionals, elected officials, and interested citizens from across
the continent (and even a few from across the water and south of the
border) converged on the New Jersey Meadowlands, just across the
Hudson River from New York City, as the Drug Policy Alliance
(http://www.drugpolicy.org) held its biennial national conference.
Proceedings opened with a bang as DPA hosted a noon press conference
to announce the release of a report it commissioned that cites the
Garden State as the nation's worst when it comes to percentage of drug
offenders in the prison population.

Hours earlier, DPA executive director Ethan Nadelmann officially
opened the conference -- the first real national movement confab since
April's NORML convention in San Francisco -- with a keynote address
outlining his and DPA's vision of the state of the struggle and where
it is headed.

Citing movement responses to the outing of Rush Limbaugh as a
pill-taker as indicative of a movement with two sides -- left
progressives and freedom-loving (or anti-statist) conservatives --
Nadelmann called for drug reformers to transcend ideological
differences. "We need to build coalitions that cross over," he said,
"They are a fundamental imperative for our future.

For drug policy reform to succeed, we need to have the right wing
fighting for freedom as well."

Conservatives opponents of drug reform, however, got no slack from
Nadelmann. "That goddamned Ashcroft is doing things to people," he
yelled in reference to the persecution of medical marijuana users and
providers in California. And he painted a picture of a foe broader
than simply drug warriors as he noted President Eisenhower's warning
of the military-industrial complex, compared it to the
prison-industrial complex, and suggested that we are now seeing the
emergence of a "Homeland Security Act-industrial complex playing to
people's fears of terrorism and drugs."

Recalling the gay rights struggles that began in the 1960s, Nadelmann
also called for drug users to come out of the closet. "Forty years
ago, everyone in America knew a homosexual," he told the crowd, "they
just didn't know they knew. But people wanted human dignity, and by
acts of personal courage they made change.

Today, everybody in America knows a drug user, but they don't know
they know one," he said. "But people are stepping out," not only in
California's medical marijuana struggle, but with AIDS and Hep C as
well. There needs to be more of this, Nadelmann said. "We have to
change the media images."

He also sought to play down divisions in the movement and pointed to
common ground. "There is a powerful, compelling case for
legalization," Nadelmann said. "Some of us don't want to go that far,
but we are united in believing that the criminal justice system should
not rule drug policy."

At the noon press conference, DPA formally unveiled a study conducted
by the Justice Policy Institute (http://www.justicepolicy.org) at its
behest. "Costs and Benefits? The Impact of Drug Incarceration in New
Jersey" raked the state for filling its prisons with a higher
percentage of drug offenders than any other. "New Jersey wastes
valuable human and financial resources by incarcerating drug offenders
who don't need to be behind bars," said JPI executive director Vincent
Schiraldi. "States like Texas and Michigan are reforming their drug
laws to divert drug offenders into treatment instead of prison.

New Jersey needs to move towards the more effective and less expensive
solution of treatment for drug offenders."

"Just about everyone in New Jersey has paid a steep price for the war
on drugs -- from prisoners and their families to cops and judges, from
people struggling with addiction to taxpayers and policymakers," said
DPA's Nadelmann. "Few states have suffered so much, and few could gain
so much from basic reforms."

The report itself paints a bleak portrait of drug policy justice in
New Jersey. Among its findings:

* With 36% of its prison population doing time for drug offenses, New
Jersey's rate is 80% more than the national average and higher than
those of usual suspects, such as three-strikes California and
lock-'em-up Texas. * Throwing drug offenders in prison has a
disproportionate impact on people of color, particularly
African-Americans. While blacks and latinos represent little more than
one-quarter of the state's population, they are 81% of the prison
population. * Features of New Jersey's sentencing structure, including
mandatory minimum sentences for drug crimes and "drug-free school
zones" have made the problem worse. * The state is spending $266
million a year in direct costs to keep its drug prisoners locked up, a
figure higher than total prison spending for one-third of other states.

The massive increase in prison spending (up $825 million over the
1980s and 1990s) accounts for 20% of this year's state budget
shortfall -- a shortfall that was made up by cutting education, health
care, and social services. * And it doesn't make any difference.
According to the study, which compared drug use with prison admissions
in 22 states, "JPI researchers tested whether states with high rates
of incarceration for drug offenses experienced a statistically
significant decrease in drug use and found there is no statistically
significant basis for believing that increasing prison admissions for
drug offenses deters drug use."

Meanwhile, even as the press conference was underway, the convention was
already in full swing, with first-day panels on topics ranging from "Got
Teenagers? How to Talk to Teens About Drugs" to "New York City: Harm
Reduction Advances," "Congress, Club Drugs, and the Business of Dancing,"
and "Drug Wars in the Americas: Views from the South." Unfortunately, this
embarrassment of riches is limited by time constraints, leaving
participants to forego some in order to see others.

The panel on "Pain, Opiates and Opiophobia" was representative of the
quality of participants brought together by DPA for the conference. It
included one of the nation's leading pain experts, Dr. Russell
Portenoy, chair of the Department of Pain Medicine and Palliative Care
at Beth Israel Medical Center, who told the audience that
"under-treatment of pain is way worse" because of doctors' fears of
prosecution. Also on the panel was Dr. Sidney Schnoll, executive
medical director for health policy for Purdue Pharma, the manufacturer
of the much praised and much maligned Oxycontin. Schnoll provided a
history lesson on the ever-tightening legal constraints faced by
doctors, as well as pointing the finger at a sensational media for
uncritically reporting death after death caused by Oxycontin --
figures that have not been matched by coroner's reports.

The panel also featured Will Rowe, executive director of the American
Pain Foundation (http://www.painfoundation.org) and Siobhan Reynolds,
executive director of the Pain Relief Network
(http://www.painreliefnetwork.org).
Rowe, who reported that an estimated 50 to 75 million Americans suffer
from under-treated chronic pain, read letter after letter from pain
patients who wrote of their inability to find doctors who would treat
them with opiates and the resulting despair, while Reynolds, a
veritable firebrand compared to her staid co-panelists, called for a
stronger defense of pain doctors and patients. "I thought the war on
drugs was like Smokey the Bear, it wasn't serious," she said. "But
they were dead serious." And now, after being educated by her
husband's endless pursuit of treatment for his chronic pain, so is
she. The drug war cannot stand in the way of treating pain, she said.
"Worrying about drug diversion and abuse is counterproductive when we
have this national health care crisis," she said.

The conference continues through Saturday. Look for additional
reporting on the conference next week.